Mohamed El-Shimy, Minister of the Public Enterprises Sector, said the ministry places the highest priority on supporting its affiliated pharmaceutical companies through comprehensive development and modernisation programmes aimed at upgrading production lines, enhancing operational efficiency, and adopting the latest technological systems. These efforts, he noted, are designed to meet domestic demand, strengthen competitiveness in export markets, and generate added value for the Egyptian economy.
El-Shimy described Cairo Pharmaceuticals as one of Egypt’s most important national industrial entities and a leading model for a strong and advanced pharmaceutical industry capable of meeting local needs and supporting exports to regional and international markets. He added that the company plays a key role in enhancing the global standing of Egyptian medicines, while commending the efforts and dedication of its workforce.
The Minister made the remarks during an extensive inspection tour of Cairo Pharmaceuticals and Chemical Industries at its Shubra facility, a subsidiary of the Holding Company for Pharmaceuticals, Chemicals and Medical Supplies. The visit aimed to review progress across the company’s operations and assess production processes following a series of comprehensive upgrades implemented in line with the latest international quality standards.
During the tour, El-Shimy inspected the company’s advanced production infrastructure, which includes 25 integrated production lines covering a wide range of pharmaceutical forms. These include plain and coated tablets, hard and soft capsules, syrups and oral drops, ointments and suppositories, effervescent and regular granulated powders, ophthalmic preparations and ampoules, highlighting the diversity of the company’s product portfolio and its capacity to meet market demand.
The visit also included the upgraded quality control laboratories, as well as the scientific research and development units, the quality assurance department and the technical development department. All operate in accordance with Good Manufacturing Practices, ensuring the production of safe and effective medicines that meet the highest international standards.
El-Shimy stressed that keeping pace with global developments in the pharmaceutical industry is a central pillar of the ministry’s strategy, underscoring the importance of investing in scientific research, innovation and continuous modernisation of production lines to ensure sustainable growth and competitive quality for Egyptian pharmaceutical products.
He emphasised that providing high-quality medicines at affordable prices remains a core objective, noting that the development of affiliated companies directly contributes to strengthening drug security, meeting citizens’ needs and reinforcing confidence in domestically produced medicines.
Company officials outlined ongoing efforts to modernise production lines using the latest systems, expand into foreign markets through new partnerships, develop competitive pharmaceutical products, increase investment in research and innovation, and strengthen corporate social responsibility initiatives.
In this context, El-Shimy reaffirmed the ministry’s full support for export expansion plans and for strengthening partnerships across different markets, highlighting their role in boosting exports of Egyptian medicines and creating new growth opportunities. He also stressed the importance of continued on-site monitoring of all affiliated companies to ensure the highest standards of production efficiency and quality.
Founded in 1962, Cairo Pharmaceuticals has more than six decades of experience and is regarded as one of the pillars of the pharmaceutical industry in Egypt and the Middle East.
The company’s financial results for the first quarter of fiscal year 2025/2026 showed a 93.2% year-on-year increase in profits, with net profits reaching EGP 143.6m, while sales rose to approximately EGP 651.8m.
Cairo Pharmaceuticals is a leading producer of several widely used medicines in the Egyptian market, including Brizolin, Spasmopyralgin, Triactin, Pyral, Novlo, Sedalin, Tussilar, Dexazone, Analerg, Dramamine and Spicton, among other essential, safe and effective pharmaceutical products serving local and regional markets.
